The primary therapeutic role of Аминазин (Chlorpromazine) is applied in addressing challenging symptom patterns across several distinct medical domains.

Stabilization of Acute Psychotic Crisis and Severe Agitation

This medication is commonly used to manage the intense symptoms of major psychiatric illnesses, particularly schizophrenia and acute mania, where it supports symptomatic management during periods of acute emotional distress, contributing to stabilization. It is applied when patients experience severe agitation, extreme emotional tension, or positive psychotic symptoms like hallucinations and delusions, and may assist with maintaining a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases.

Control of Intractable Nausea, Vomiting, and Refractory Motor Symptoms

Аминазин provides supportive symptomatic relief for specific, difficult-to-treat physical conditions outside of psychiatric care. It is used to control severe, persistent nausea and vomiting that may create noticeable physiological strain, and also offers support to ease the overall symptom burden of persistent hiccups. This use is relevant in conditions marked by increased physiological stress, such as in managing symptoms of Acute Intermittent Porphyria.

Supportive Management of Acute Behavioral and Physical Disturbances

The medicine serves as an adjunctive therapeutic aid in challenging clinical scenarios. This includes managing severe behavioral problems—such as explosive hyperactivity and combativeness—in specific pediatric patients, and providing support to ease the muscle stiffness and spasms associated with tetanus. It may also contribute to improved comfort by addressing patient restlessness and apprehension during pre-operative care.

---

• Indications Summary: The medication is applied in conditions involving significant symptom expression, including schizophrenia, acute mania, intractable hiccups, control of severe nausea and vomiting, management of severe behavioral problems in children, adjunctive treatment of tetanus, and symptomatic support in Acute Intermittent Porphyria.

  ---

  “The primary benefit provided by this medication is supportive symptomatic relief, which assists with maintaining a sense of stability and improving comfort during periods of acute or overwhelming symptoms.”

  ---

Quick Fact: Symptomatic Support in Acute Episodes
Core Symptom Managed	Severe agitation, delusions, and hallucinations in acute psychosis.
Practical Benefit	Contributes to stabilization and helps ease distress during crises.
Non-Psychiatric Use	Easing the symptom burden of intractable hiccups and severe vomiting.

This section outlines the official eligibility and non-eligibility for Аминазин (Chlorpromazine) based strictly on regulatory labeling.

Contraindicated Populations

The medicine must not be used by patients with:

• Known hypersensitivity to chlorpromazine or other phenothiazines.
• A comatose state or severe Central Nervous System (CNS) depression.
• Circulatory collapse or severe hypotension.
• Bone marrow depression or active liver disease.

Age and Developmental Limitations

Population	Regulatory Status
Infants (<1 year)	Use not established or only for life-saving necessity, with caution.
Children (ge 1 year)	Approved for specific indications, such as severe behavioral problems.
Older Adults (Geriatric)	Use for dementia-related psychosis is not approved due to increased mortality risk; lower initial doses are required.

Condition-Specific Restrictions

Use requires extreme caution or is limited in patients with poorly controlled seizure disorder, renal or hepatic impairment, glaucoma, and prostatic hypertrophy.

Pregnancy and Lactation

• Pregnancy: Safety has not been established. Use is not recommended unless the potential benefit clearly outweighs the possible hazards. Neonates exposed in the third trimester are at risk for withdrawal symptoms.
• Lactation: Use is not recommended as the drug is excreted into breast milk. A decision must be made to discontinue either the drug or breastfeeding.

Aminazine (chlorpromazine) can interact with a wide range of medications, supplements, and substances, potentially altering its effects or increasing the risk of adverse reactions. It is crucial to inform a healthcare provider of all products currently being taken.

Increased Sedation and CNS Depression

Concurrent use of Aminazine with other Central Nervous System (CNS) depressants can lead to enhanced sedation, drowsiness, and impaired motor function. This includes:

• Alcohol (Consumption must be avoided)
• Opioids and certain pain medications
• Benzodiazepines and other sleep aids or anxiety medications
• Antihistamines (especially sedating types)
• Barbiturates

Cardiovascular Risk

Combining Aminazine with certain drugs may increase the risk of serious heart rhythm changes (QT prolongation), including life-threatening arrhythmias. Avoid co-administration with other medications known to prolong the QT interval, such as specific antiarrhythmics (e.g., quinidine, sotalol, amiodarone) and certain other antipsychotics or antidepressants.

Altered Drug Efficacy

Aminazine may antagonize the therapeutic effects of certain medications, including epinephrine (adrenaline) and some antidiabetic agents. Antacids and agents like benztropine may reduce the absorption of Aminazine, leading to decreased effectiveness.

Interaction Type	Examples of Affected Agents/Products
Increased Low Blood Pressure Risk	MAOIs (Monoamine Oxidase Inhibitors), Thiazide diuretics
Increased Anticholinergic Effects	Other anticholinergics (e.g., benztropine)

Close monitoring or dose adjustments may be required when using Aminazine with drugs that inhibit or induce the CYP2D6 enzyme system.

How Аминазин Works

The mechanism of action for Aminazine (Chlorpromazine) is primarily rooted in its role as a broad-spectrum receptor antagonist within the central nervous system.

Dopamine Receptor Blockade and Signal Dampening

Aminazine's most significant action is the blockade of dopamine D2 receptors in various brain pathways. This action suppresses excessive dopaminergic signaling, which is a core mechanism contributing to the overall dampening of overactive physiological responses and influences neural signaling dynamics.

Broad Neurotransmitter Modulation and System Regulation

The drug also engages a diverse set of other receptors, including histamine H1, alpha1-adrenergic, and serotonin receptors. This wide-ranging antagonism alters signaling dynamics across multiple neural and humoral pathways, leading to systemic physiological adjustments like CNS depression and a reduction in sympathetic tone.

Influence on Neuro-Regulatory Cascades

By initiating immediate receptor interference, Aminazine triggers molecular cascades that influence the pathways' regulatory feedback mechanisms. This action is relevant in modulating processes related to long-term pathway adjustment within the targeted pathways, contributing to altered downstream signaling consequences of persistent mediator activity, and resulting in distinct physiological adjustments.

The administration of Аминазин (Chlorpromazine) is determined by the specific clinical scenario, utilizing routes that include oral (PO), intramuscular (IM), and intravenous (IV) delivery. For long-term oral maintenance, the adult dosing regimen typically begins with a low starting dose, such as 25 mg to 75 mg daily in divided portions, which may be gradually increased (titrated) until the effective maintenance range, often between 200 mg and 800 mg per day, is reached. The oral formulations are generally taken in divided portions throughout the day.

For rapid management in acute settings, the parenteral route is used. An initial IM dose is typically 25 mg, with subsequent injections potentially administered after one to four hours as necessary. The IV route is reserved for controlled procedural use, such as the management of intractable hiccups. IV administration requires the solution to be diluted to a concentration not exceeding 1 mg/mL and must be administered by slow infusion with the patient lying flat in bed.

Dose modifications are utilized for specific groups. Older and debilitated adults are typically started on a significantly lower initial dose (e.g., 1/3 to 1/2 the usual adult dose), and any increases follow a more gradual schedule. Dosing for pediatric patients (age 6 months and older) is calculated based on body weight (e.g., 0.5 mg/kg per dose). Furthermore, liquid oral concentrate formulations require dilution in a beverage or semi-solid food immediately prior to consumption.

Research evidence / Overview of studies for Аминазин

Evidence for Use in Acute Psychotic Crises

Research examined the use primarily in adults with schizophrenia and the acute manic phase of bipolar disorder; these are conditions presenting with cycles of stability and flare-ups often associated with severe agitation and sensory disturbances. The evidence comes from many older Randomized Controlled Trials (RCTs) and systematic reviews that explored short-term symptom changes and how quickly measured outcomes evolved, including documentation of the frequency of symptom return over time.

Despite the large volume of evidence, a significant portion of the foundational data is documented by reviewers as having low methodological quality when evaluated by current standards. Furthermore, long-term effects are not fully established, and there remains limited information for long-term outcomes regarding the observation of maintained status. Certainty remains low regarding consistent long-term results, and findings were mixed across studies that monitored the frequency of symptom return. Studies described patterns of difference when compared against other pharmacological agents in research settings.

Evidence for Use in Non-Psychiatric Acute Conditions

Аминазин was evaluated in settings that include acute physical conditions, such as intractable hiccups and severe, persistent nausea and vomiting. The evidence for these uses often relies on a structure of observational studies, case reports, and case series, rather than large-scale, contemporary randomized controlled trials. Research explored short-term symptom changes in these conditions, using outcomes related to systemic or functional imbalance, such as measurements of hiccup activity or vomiting frequency.

For these specific indications, the evidence is limited, and there is a recognized paucity of high-quality randomized data. The use of the medicine for intractable hiccups and supportive care in conditions like tetanus is primarily derived from evidence derived from settings with varying symptom burdens. For these uses, comparative evidence is lacking against other pharmacological agents.

Evidence in Special Populations and Research Gaps

Research explored the use of the medication in specific groups, including pediatric patients and older adults. For children, studies focused on managing severe behavioral problems; however, the research base for this specific pediatric indication is often documented by reviewers as limited, dated, and of lower methodological quality. For all special populations, sample sizes were modest, and data for certain groups remain insufficient for drawing broad conclusions.

Overall, the reliance on historical data where evidence quality varies across studies remains a major limitation. Long-term effects are not fully established, and comparative evidence is lacking in large-scale contemporary research against many newer comparator agents.

Key Studies & References

1. Label: CHLORPROMAZINE tablet - DailyMed (Official FDA Regulatory Monograph)

Common questions about Аминазин (FAQ)

---

Q: Does Aminazine interact with MAOIs and what are the effects?

Official information indicates that using this medicine concurrently with Monoamine Oxidase Inhibitors (MAOIs) is associated with an increased risk of severe hypotension. Hypotension is a condition where blood pressure drops too low, which may lead to symptoms such as dizziness.

Q: Which patients must start on a significantly lower initial dose of the drug?

Official prescribing information advises that a lower initial dose and a more gradual increase are typically used for older, debilitated, or emaciated patients. This adjustment is used because these groups may be more susceptible to effects like very low blood pressure (hypotension).

Q: How should the liquid oral concentrate of Aminazine be prepared for use?

Official instructions state the oral liquid concentrate should be diluted immediately before consumption. It should be mixed with a liquid or semi-solid food, such as fruit juice, milk, soup, or pudding.

Q: What are the signs or symptoms of the serious adverse reaction Neuroleptic Malignant Syndrome (NMS)?

Neuroleptic Malignant Syndrome (NMS) is a rare but serious reaction. Regulatory documents describe its clinical features as including hyperpyrexia (very high fever), muscle rigidity (stiffness), altered mental status, and autonomic instability. Autonomic instability includes signs such as irregular pulse or blood pressure and excessive sweating.

Q: Are there any lifestyle activities or foods that are specifically restricted while taking this medication?

Official safety information advises caution about activities requiring alertness (e.g., operating vehicles or machinery), especially at the start of therapy, due to potential impairment. Furthermore, regulatory warnings indicate that the use of alcohol should be avoided.

Q: How quickly does Aminazine begin to act after an oral dose for psychiatric use?

Studies and official information indicate that following an oral dose, the onset of action for this medication is generally reported to occur within 15 to 60 minutes after administration.

Q: How long do I need to take Aminazine tablets before the doctor re-evaluates my dose?

Official information for psychotic disorders suggests that once a dosage level achieves symptom control, it is often maintained for approximately two weeks before considering a gradual reduction to the lowest effective maintenance level.

The storage and disposal of Aminazine (Chlorpromazine) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

Official Storage and Handling

Requirement Type	Labeled Constraint
Temperature Range	Store below 25 C at room temperature.
Environmental Protection	Protect the product from light, excess heat, and moisture.
Packaging Rules	Keep tablets in the original package and the container tightly closed.
Child Safety	Store the medicine out of the sight and reach of children.

For the injectable solution, integrity must be confirmed by visually checking for particulate matter or discoloration before use.

Disposal Requirements

All unused medicinal product or waste material must be disposed of in accordance with local requirements. The official protocol advises against disposal via household waste or wastewater to comply with environmental regulations.